Prohibited Chemical E Ver4.00.Xlsx
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
Toxicology Times
TOXICOLOGY (800) 677-7995 TIMES www.sdrl.com A FREE Monthly Newsletter for Substance Abuse and Opioid Treatment Volume 5, Issue 7 Programs from San Diego Reference Laboratory July, 2015 Amphetamines (Part 1) Dr. Joseph E. Graas, Scientific Director most often used in inhalers and does not tite, increased stamina and physical energy, Dr. Edward Moore, Medical Director have the central nervous system activity nor increased sexual response/drive, involuntary any addictive properties. All of the com- body movements, increased perspiration, The term “amphetamines” has come to mean pounds that have the structure of hyperactivity, nausea and increased heart rate. a class of endogenous neurotransmitters that phenylethylamine will have this mixture of d This drug is highly addictive and tolerance stimulate the sympathetic nervous system. and l molecules. In the production of these develops quickly. Withdrawal is an extremely This is a broad class of various substituted drugs they are usually noted as a racemic unpleasant experience. A few street names derivatives of phenylethylamine. This grow- mixture, or specifically, as the d or l com- for the drug are amp, speed, crank, dolls and ing class of structurally related molecules may pound. To properly evaluate this family of crystal. also stimulate the sympathetic nervous sys- compounds known as sympathomimetic tem in many different ways, such as affecting amines, amphetamines or phenylethylamine, Methamphetamine was developed by the the re-release of neurotransmitters or pre- it is best done by describing each member of Japanese in 1919 and used during World War venting the re-uptake of neurotransmitters, the class: amphetamine , methampheta- II to help soldiers stay alert and energize hallucinogens, anorectics, bronchodilators mine , phentermine , phenylpropanola- factory workers. -
Prohibited Chemical Cn Ver4.00.Xlsx
修订日：2021/7/15 Nitto集团 禁止含有的化学物质 Ver 4.00 分析 备注 物质 化学物质或物质群 阈值 数据 (记载的法律法规只用于对象物质的特定， 例举表 要否 其适用范围不作参考) (不使用保证书中收录的物质) EU REACH法规 AnnexⅩⅦ 未有意添加，且含量不超过1000ppm（不包 石棉类 需要 需要分析的仅限于滑石等可能有石棉混入的 表A 括1000ppm） 矿物原料 ― 部分偶氮染料/颜料（生成特定胺） 未有意添加 EU REACH法规 AnnexⅩⅦ 未有意添加，且镉含量不超过 镉及其化合物 需要 2011/65/EU(EU RoHS2指令) ５ppm（不包括5ppm） 未有意添加，且六价铬含量不超过 六价铬化合物 需要 2011/65/EU(EU RoHS2指令) 100ppm（不包括100ppm） 未有意添加，且铅含量不超过100ppm（不包 铅及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm） 未有意添加，且汞含量不超过100ppm（不包 汞及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm） 未有意添加，且PBB含量不超过100ppm（不 多溴联苯类（PBB类） 需要 2011/65/EU(EU RoHS2指令) 包括100ppm） 未有意添加，且PBDE含量不超过100ppm（不 2011/65/EU(EU RoHS2指令) 多溴联苯醚类（PBDE类） 需要 包括100ppm） 包括十溴联苯醚 蒙特利尔议定书 臭氧层破坏物质 未有意添加 ― 同时禁止在制造工序中使用 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸（2-乙基己基）酯(DEHP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸二正丁酯(DBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸丁基苄酯(BBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸二异丁酯(DIBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 斯德哥爾摩公約 Annex A 多氯联苯类（PCB类） 未有意添加 ― 第一种特定化学物质（日本 化学物质的审 查及制造等的规制法）（以下简称化审法） 多氯三联苯类（PCT类） 未有意添加 ― EU REACH法规 AnnexⅩⅦ ― 多氯萘（氯原子数大于等于2） 未有意添加 化审法第一种特定化学物质 放射性物质 未有意添加 ― 使用放射性同位素的分析仪器除外 ― 斯德哥爾摩公約 Annex A 短链氯化石蜡（C10－C13） 未有意添加 化审法第一种特定化学物质 EU REACH法规 AnnexⅩⅦ 三丁基氧化锡（TBTO） 未有意添加 ― 化审法第一种特定化学物质 未有意添加，且含量不超过25ppb（不包括 全氟辛酸（PFOA）和其盐类及其PFOA的相关物 POPs公约 Annex A 25ppb）（PFOA相关物质不超过1000ppb） ― 质 EU POPs规则 附属书1 （不包括1000ppb） 未有意添加，且含量不超过25ppb（不包括 全氟乙基磺酸(PFHxS)及其盐类及PFHxS 相关 25ppb）（PFHxS相关物质不超过1000ppb） ― POPs公约 Annex A 物质 （不包括1000ppb） 三取代有机锡化合物 EU REACH法规 AnnexⅩⅦ 未有意添加 ― （包括TBT类、TPT类）（注1） -
Monoamine Reuptake Inhibitors in Parkinson's Disease
Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters. -
Comprehensive Multi-Analytical Screening Of
COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA, -
Amphetamine Use Among Workers with Severe Hyperthermia
Morbidity and Mortality Weekly Report Notes from the Field Amphetamine Use Among Workers with Severe National Weather Service observation stations, the maximum Hyperthermia — Eight States, 2010–2019 outdoor heat index (a metric that combines temperature and Andrew S. Karasick, MD1,2; Richard J. Thomas, MD1; relative humidity into a single number that represents how hot Dawn L. Cannon, MD1; Kathleen M. Fagan, MD1; Patricia A. Bray, MD1; the conditions feel to humans) ranged from 86°F to 107°F 1 1 Michael J. Hodgson, MD ; Aaron W. Tustin, MD (median = 97°F) on the days of the nine incidents. Seven of the nine workers died, and two survived life-threat- Workers can develop hyperthermia when core body tem- ening illnesses. Peak body temperature ranged from 103°F to perature rises because of heat stress (environmental heat plus 110.6°F (39.4°C to 43.7°C) in eight workers with confirmed metabolic heat from physical activity) (1). Amphetamines are severe hyperthermia. In one fatality with no premortem body central nervous system stimulants that can induce hyperthermia temperature measurement, the medical examiner suspected independently or in combination with other risk factors (2). that hyperthermia was a significant contributing condition, During 2010–2016, the Directorate of Technical Support and based upon the circumstances (i.e., death occurred in a hot Emergency Management’s Office of Occupational Medicine environment after strenuous activity on a hot day) and lack and Nursing (OOMN), at the Occupational Safety and Health of anatomic evidence of an alternative cause of death (e.g., Administration (OSHA), identified three workers with fatal myocardial infarction). -
Chiral Separation of Methamphetamine and Amphetamine on an Agilent Infinitylab Poroshell 120 Chiral-V Column with Detection by LC/MS
Application Note Clinical Research Chiral separation of methamphetamine and amphetamine on an Agilent InfinityLab Poroshell 120 Chiral-V column with detection by LC/MS Authors Abstract Carl Griffin and William Long An Agilent InfinityLab Poroshell 120 Chiral-V 2.1 × 150 mm, 2.7 μm column Agilent Technologies, Inc. (p/n 683775-604) was used to analyze methamphetamine and amphetamine Wilmington, DE, USA by LC/MS, using a mobile phase of methanol with 0.1 % acetic acid and 0.02 % ammonium hydroxide. The analysis was accomplished in 5 minutes, with a resolution Rs of 1.9 or better for racemic amphetamine and methamphetamine. Introduction H NH Experimental N 2 Superficially porous particle columns are An Agilent 1290 Infinity LC system CH3 a popular tool in liquid chromatography. with an Agilent 6460 triple quadrupole Superficially porous particle columns (S)-(+)-Methamphetamine (S)-(+)-Amphetamine LC/MS was used in this experiment. The generate high efficiency at lower Dextromethamphetamine Dextroamphetamine system was modified from its standard pressure relative to their totally porous configuration to have low system volume 1 particle column counterparts . This is H NH and dispersion. Table 1 shows the primarily due to a shorter mass transfer N 2 instrument configuration details. Table 1 distance and substantially narrower CH lists the Agilent InfinityLab Poroshell 120 particle size distribution of the particles 3 Chiral-V 2.1 × 150 mm, 2.7 μm column in the column2. The current trend with (R)-(–)-Methamphetamine (R)-(–)-Amphetamine used in this work. Table 2 shows the LC superficially porous particles is reducing Levomethamphetamine Levoamphetamine and MS parameters. -
Drug Early Warning from Re-Testing Biological Samples: Allen County, Indiana
Drug Early Warning from Re-Testing Biological Samples: Allen County, Indiana Office of National Drug Control Policy Executive Office of the President July 2018 ACKNOWLEDGMENTS This report was funded by Cooperative Agreement #G1599ONDCP04A awarded by the Executive Office of the President, Office of National Drug Control Policy (ONDCP), to the University of Maryland’s Center for Substance Abuse Research (CESAR). Eric D. Wish, Ph.D. (Principal Investigator), Amy Billing, MSSA, and Eleanor Erin Artigiani, MA, produced this report. Fe Caces, Ph.D., served as reviewer and Project Manager at ONDCP and Terry Zobeck, Ph.D., also served as a reviewer. We are grateful to the criminal justice and laboratory staff that worked with us on this project. Without the support and assistance of the Allen County Adult Probation Program and the HOPE Probation staff, this project could not have been completed. The independent laboratory analyses for this report were conducted by the Armed Forces Medical Examiner System (AFMES) Laboratory. We would like to thank the specific staff listed below: Allen County Adult Probation (HOPE Probation - Indiana) Judge Wendy Davis Eric Zimmerman, Director of Court Services/Chief Probation Officer Steve Keele Thomas Felts Armed Forces Medical Examiner System, Division of Forensic Toxicology Dr. Jeff Walterscheid Lt. Commander Pedro Ortiz Major Lynn Wagner CTR Anastasia Berrier CTR Kimberley Heine CTR Theresa Hippolyte CTR Paul Kaiser ii Disclaimer The information and opinions expressed herein are the views of the authors and do not necessarily represent the views of the Office of National Drug Control Policy (ONDCP) of the Executive Office of the President, or any other agency of the Federal Government. -
Testing for Amphetamine and Methamphetamine Abuse Using
Healthcare & Life Sciences Accurate Biological Testing for Amphetamine and Methamphetamine Abuse Using Chiral HPLC and MS Detection In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine. Introduction from several tens to several hundreds of milligrams, depending on Methamphetamine and amphetamine, powerful CNS stimulants the purity and the isomeric composition, and will metabolize to 3 that have a variety of ethical uses, have side effects of increased amphetamine and 4-hydroxymethamphetamine. Amphetamine confidence, sociability, and energy that have resulted in their metabolizes mainly to 1-phenyl-2-propanone, with smaller extensive abuse as recreational psychoactive drugs. This extends to amounts of 4-hydroxyamphetamine. However, since up to 54% their abuse in sports because of the additional properties of increased of methamphetamine is excreted unchanged and 10-23% as mental alertness and suppression of fatigue.1 Negative side effects amphetamine following oral ingestion, it is usually the parent drug 1 include hypertension and tachycardia. In the usually uncontrolled that is monitored. situations of drug abuse, they exhibit similar psychoactive Culpability for the illicit use of amphetamine and methamphetamine effects, although amphetamine is generally less potent than rests on the ability to distinguish the contribution to the measured methamphetamine. abused product from possible alternative sources of the L-enantiomer. Illicit use of these drugs continues to be high. Public Health Therefore, the separation of the enantiomers is a more accurate England recently reported that the number of people stating their approach for testing. A chiral method can also be used to indicate main injecting drug to be amphetamines and amphetamine-type the synthetic route that was used by the illegal source, which can be substances (such as mephedrone) nearly tripled between 2002 and useful as part of a criminal investigation. -
Medicines and Related Substances Act No. 101 of 1965
MEDICINES AND RELATED SUBSTANCES ACT NO. 101 OF 1965 [View Regulation] [ASSENTED TO 19 JUNE, 1965] [DATE OF COMMENCEMENT: 1 APRIL, 1966] (Afrikaans text signed by the State President) This Act was published in Government Gazette 40869 dated 26 May, 2017. as amended by Drugs Control Amendment Act, No. 29 of 1968 Drugs Control Amendment Act, No. 88 of 1970 Drugs Laws Amendment Act, No. 95 of 1971 Drugs Control Amendment Act, No. 65 of 1974 Medicines and Related Substances Control Amendment Act, No. 19 of 1976 Health Laws Amendment Act, No. 36 of 1977 Medicines and Related Substances Control Amendment Act, No. 17 of 1979 Medicines and Related Substances Control Amendment Act, No. 20 of 1981 Transfer of Powers and Duties of the State President Act, No. 97 of 1986 [with effect from 3 October, 1986] Businesses Act, No. 71 of 1991 [with effect from 24 May, 1991] Medicines and Related Substances Control Amendment Act, No. 94 of 1991 General Law Amendment Act, No. 49 of 1996 [with effect from 4 October, 1996] Abolition of Restrictions on the Jurisdiction of Courts Act, No. 88 of 1996 [with effect from 22 November, 1996] Medicines and Related Substances Control Amendment Act, No. 90 of 1997 Medicines and Related Substances Amendment Act, No. 59 of 2002 Judicial Matters Amendment Act, No. 66 of 2008 [with effect from 17 February, 2009] Medicines and Related Substances Amendment Act No. 72 of 2008 Medicines and Related Substances Amendment Act, No. 14 of 2015 GENERAL NOTE There is a discrepancy between the English and Afrikaans texts of section 1 of Act No. -
Descriptive, Observational Study of Pharmaceutical and Non-Pharmaceutical Arrests, Use, and Overdoses in Maine
Open access Research BMJ Open: first published as 10.1136/bmjopen-2018-027117 on 29 April 2019. Downloaded from Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine Kevin J Simpson,1 Matthew T Moran,1 Michelle L Foster,2 Dipam T Shah,1 Daniel Y Chung,1 Stephanie D Nichols,3 Kenneth L McCall,4 Brian J Piper1 To cite: Simpson KJ, Moran MT, ABSTRACT Strengths and limitations of this study Foster ML, et al. Descriptive, Objectives The Maine Diversion Alert Program grants observational study of healthcare providers access to law enforcement data on ► All arrests involving illicit or licit drugs reported to pharmaceutical and non- drug charges. The objectives of this report were to analyse pharmaceutical arrests, use, and the Diversion Alert Program of Maine in 2017 were variations in drug charges by demographics and examine overdoses in Maine. BMJ Open examined. recent trends in arrests, prescriptions of controlled 2019;9:e027117. doi:10.1136/ ► Controlled substance transactions reported to the substances and overdoses. bmjopen-2018-027117 Drug Enforcement Administration were evaluated. Design Observational. ► Drug-induced deaths (n=2432) reported to the ► Prepublication history and Setting Arrests, controlled prescription medication Maine Office of Medical Examiner were analysed. additional material for this distribution and overdoses in Maine. paper are available online. To ► These complementary results from Maine may not Participants Drug arrestees (n=1272) and decedents view these files, please visit generalise to larger states with younger or more di- (n=2432). the journal online (http:// dx. doi. verse populations. org/ 10. 1136/ bmjopen- 2018- Primary outcome measures Arrestees were analysed by 027117). -
Neurochemical Studies of Attention-Deficit/ Hyperactivity Disorder Medications in the Striatum and Nucleus Accumbens of the Fischer 344 Rat
University of Kentucky UKnowledge University of Kentucky Doctoral Dissertations Graduate School 2006 NEUROCHEMICAL STUDIES OF ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER MEDICATIONS IN THE STRIATUM AND NUCLEUS ACCUMBENS OF THE FISCHER 344 RAT Barry Matthew Joyce University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Joyce, Barry Matthew, "NEUROCHEMICAL STUDIES OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER MEDICATIONS IN THE STRIATUM AND NUCLEUS ACCUMBENS OF THE FISCHER 344 RAT" (2006). University of Kentucky Doctoral Dissertations. 238. https://uknowledge.uky.edu/gradschool_diss/238 This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of UKnowledge. For more information, please contact [email protected]. ABSTRACT OF DISSERTATION Barry Matthew Joyce The Graduate School University of Kentucky 2006 NEUROCHEMICAL STUDIES OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER MEDICATIONS IN THE STRIATUM AND NUCLEUS ACCUMBENS OF THE FISCHER 344 RAT ____________________________ ABSTRACT OF DISSERTATION ____________________________ A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the College of Medicine at the University of Kentucky By Barry Matthew Joyce Lexington, Kentucky Director: Dr. Greg Gerhardt, Professor of Anatomy and Neurobiology Lexington, Kentucky 2006 Copyright © Barry Matthew Joyce 2006 ABSTRACT OF DISSERTATION NEUROCHEMICAL STUDIES OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER MEDICATIONS IN THE STRIATUM AND NUCLEUS ACCUMBENS OF THE FISCHER 344 RAT Stimulant medications such as D-amphetamine, mixed-salts (75% D- and 25% L-) amphetamine; Adderall®, and methylphenidate are first-line treatments for Attention-Deficit/Hyperactivity Disorder (ADHD).